Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046045/SGN-35T in Adults With Advanced Malignancies
NCT06120504Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SGN-35T in lymphoma, sponsored by Pfizer. Primary endpoints: Adverse Events at 1 year, Laboratory Abnormalities at 1 year and 3 more. Started Feb 2024; status: terminated.
02
Drugs
SGN-35T
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT06120504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120504.